enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Wandering can be deadly for the growing number of US ... - AOL

   www.aol.com/wandering-deadly-growing-number-us...

   A 2021 Capital Caring Health and WebMD national survey found that while 9 in 10 aging adults want to age in place, the prevalence of Alzheimer's and the risk of wandering can put them in danger ...

3. Wandering (dementia) - Wikipedia

   en.wikipedia.org/wiki/Wandering_(dementia)

   Tracking devices of several kinds have been evaluated. [8] [9] Much of the literature on wandering concerns institutional residents. Studies on wandering from private residences are insufficient for comparison of prevention via drugs versus other methods. [10] The risk of wandering can be reduced by several low-tech and minimally intrusive ...

4. Project Lifesaver - Wikipedia

   en.wikipedia.org/wiki/Project_Lifesaver

   The organization was formed to develop a program for locating missing persons with dementia, epilepsy, Alzheimer's disease, autism, Down syndrome and other disabilities. [2] [3] [4] The program involves attaching a radio transmitter device to the wrist or ankle of persons at-risk of wandering. [5]

5. Electronic tagging - Wikipedia

   en.wikipedia.org/wiki/Electronic_tagging

   Electronic tagging is a form of surveillance that uses an electronic device affixed to a person. In some jurisdictions, an electronic tag fitted above the ankle is used for people as part of their bail or probation conditions. It is also used in healthcare settings and in immigration contexts.

6. Your Healthy Family: Wandering is a big risk for people with ...

   www.aol.com/news/healthy-family-wandering-big...

   Alzheimer's Disease is the most common cause of dementia in older adults. It can affect people in different ways, including making some wander. Your Healthy Family: Wandering is a big risk for ...

7. Alzheimer's researchers say brain stimulation device ... - AOL

   www.aol.com/alzheimers-researchers-brain...

   The new study, a phase 2 clinical trial, included 32 volunteers with Alzheimer’s disease, aged 56 to 88 at the start of the study, who were followed for 52 weeks. Sixteen of the participants who ...